Search

Displaying results 4431 - 4440 of 7283 in total
  1. Drug

    Lotilaner

    go.drugbank.com/drugs/DB17992
    ApprovedInvestigationalVet approved

    Lotilaner is an ectoparasiticide that is a member of the isoxazoline family of compounds. … [A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551]

  2. Drug

    Bamlanivimab

    go.drugbank.com/drugs/DB15718
    ApprovedInvestigational

    Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. … [L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020.

  3. Target

    ATPase GET3

    go.drugbank.com/bio_entities/BE0000750
    TargetHumans

    This complex then targets to the endoplasmic reticulum by membrane-bound receptors GET1/WRB and CAMLG/GET2, where the tail-anchored protein is released for insertion.

    Synonyms: Transmembrane domain recognition complex 40 kDa ATPase subunit
  4. Drug

    Idelalisib

    go.drugbank.com/drugs/DB09054
    ApprovedInvestigational

    Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic … For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other

    Categories: Class Ia Phosphatidylinositol 3-Kinase, antagonists & inhibitors, P-glycoprotein substrates with a Narrow Therapeutic Index
  5. Drug

    AD 337

    go.drugbank.com/drugs/DB05725
    Investigational

    AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia).

  6. Drug

    DR-01

    go.drugbank.com/drugs/DB18258
    Investigational

    DR-01 is a monoclonal antibody directed against human CD94.

  7. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. … Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of

    Categories: Complex Mixtures
  8. Drug

    Propiomazine

    go.drugbank.com/drugs/DB00777
    Approved

    Propiomazine, an atypical antipsychotic agent, is used to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia. Future uses may include the treatment...

    Categories: Dopamine D2 Receptor Antagonists
  9. Drug

    Eflornithine

    go.drugbank.com/drugs/DB06243
    ApprovedInvestigationalWithdrawn

    a 68% reduction in the risk of death were observed. … This approval is based on positive results obtained from a multi-site, single-arm, externally controlled study of children with high-risk neuroblastoma, where a 52% reduction in the risk of relapse and

  10. Drug

    Telotristat ethyl

    go.drugbank.com/drugs/DB12095
    Approved

    Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. … [L43342] It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.